World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
102
Citations
59743
World Ranking
7503
National Ranking
222

Overview

Alan S. Coates is affiliated with the University of Sydney in Australia and has an extensive body of research primarily focused on breast cancer and related medical fields. Their work addresses multiple aspects of breast cancer, including therapies, treatment studies, and hormone-related effects.

Coates has published extensively in major academic venues. Frequent publication venues include:

  • Annals of Oncology
  • Journal of Clinical Oncology
  • Breast Cancer Research and Treatment
  • Cancer Research
  • Cancer

Their recent papers span from 2020 to 2023 and focus on endocrine therapy, hormonal effects, and genomic characterization. Selected works include:

  • "Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials," 2022, Journal of Clinical Oncology
  • "Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT," 2022, Journal of Clinical Oncology
  • "Genomic characterisation of hormone receptor-positive breast cancer arising in very young women," 2023, Annals of Oncology
  • "Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy," 2020, Breast Cancer Research and Treatment
  • "Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy," 2021, Annals of Oncology

Alan S. Coates collaborates frequently with a range of researchers, notable among them are:

  • Marco Colleoni
  • Richard D. Gelber
  • Aron Goldhirsch
  • Meredith M. Regan
  • Harold J. Burstein

The main academic fields of study for Coates' work are Medicine and Biochemistry, Genetics and Molecular Biology. Their research incorporates several subfields, including:

  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Genetics
  • Oncology
  • Physiology

Within these fields, their primary research topics focus on:

  • Advanced Breast Cancer Therapies
  • Breast Cancer Treatment Studies
  • Estrogen and related hormone effects
  • HER2/EGFR in Cancer Research
  • Cancer survivorship and care
  • Sexual function and dysfunction studies
  • Genital Health and Disease

Best Publications

  • Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

    A. Goldhirsch;W.C. Wood;A.S. Coates;R.D. Gelber

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    A Goldhirsch;E P Winer;A S Coates;R D Gelber

  • A Randomized Trial Of Exemestane After Two To Three Years Of Tamoxifen Therapy In Postmenopausal Women With Primary Breast Cancer.

    R. C Coombes;E. Hall;L. J. Gibson;R. Paridaens

  • A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

    Beat Thürlimann;Aparna Keshaviah;Alan S Coates

  • Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

    A. S. Coates;E. P. Winer;A. Goldhirsch;R. D. Gelber

  • Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009

    Aron Goldhirsch;J. N. Ingle;R. D. Gelber;A. S. Coates

  • Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

    Mark R Middleton;J J Grob;N Aaronson;G Fierlbeck

  • Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005

    A. Goldhirsch;J. H. Glick;R. D. Gelber;A. S. Coates

  • Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial

    Viviana Galimberti;Bernard F. Cole;Bernard F. Cole;Stefano Zurrida;Giuseppe Viale;Giuseppe Viale

  • Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007

    A. Goldhirsch;W. C. Wood;R. D. Gelber;A. S. Coates

  • On the receiving end—patient perception of the side-effects of cancer chemotherapy

    Alan Coates;Suzanne Abraham;S.B. Kaye;Timothy Sowerbutts

  • Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

    Alan S. Coates;Aparna Keshaviah;Beat Thürlimann;Henning Mouridsen

  • Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

    RC Coombes;LS Kilburn;CF Snowdon;R Paridaens

  • Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen

    Mitch Dowsett;Jack Cuzick;Jim Ingle;Alan Coates

  • Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer

    Aron Goldhirsch;William C. Wood;Richard D. Gelber;Alan S. Coates

  • Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer

    Aron Goldhirsch;John H. Glick;Richard D. Gelber;Alan S. Coates

  • Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    Bernard Asselain;William Barlow;John Bartlett;Jonas Bergh

  • Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

    Olivia Pagani;Meredith M. Regan;Barbara A. Walley;Gini F. Fleming

  • Adjuvant ovarian suppression in premenopausal breast cancer

    Prudence A. Francis;Prudence A. Francis;Meredith M. Regan;Gini F. Fleming;István Láng

  • Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies.

    Alan Coates;Val Gebski;James F. Bishop;Peter N. Jeal

Frequent Co-Authors

Richard D. Gelber
Richard D. Gelber Harvard University
Aron Goldhirsch
Aron Goldhirsch European Institute of Oncology
Karen N. Price
Karen N. Price Frontier Science Foundation
Marco Colleoni
Marco Colleoni European Institute of Oncology
Meredith M. Regan
Meredith M. Regan Harvard University
Giuseppe Viale
Giuseppe Viale University of Milan
Beat Thürlimann
Beat Thürlimann Kantonsspital St. Gallen
John F. Forbes
John F. Forbes University of Limerick
Gini F. Fleming
Gini F. Fleming University of Chicago
Patrick Neven
Patrick Neven KU Leuven

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students considering a medical career in the USA, a variety of online degrees and expedited career pathways are available. These programs offer flexible options for working professionals or those seeking a faster route into the healthcare field.

Aspiring nurses and advanced practice providers can explore the shortest dnp program online to rapidly achieve the highest clinical nursing degree. Some may prefer the easy dnp programs that balance rigorous academics with accessible requirements. Licensed Practical Nurse hopefuls can benefit from a lpn fast track program to quickly enter the workforce. Mental health professionals can specialize further with the shortest pmhnp program, advancing their roles in psychiatric care.

These online pathways provide accelerated, convenient learning opportunities, making it easier for individuals to expand their skills and advance their medical careers without putting their lives on hold.

Best Scientists Citing Alan S. Coates

Trending Scientists